摘要
目的 :探讨美罗华联合 CEOP方案治疗复发性非霍奇金淋巴瘤 (NHL)的疗效及安全性。方法 :2 3例复发的 B细胞 NHL 患者 ,其中 6例接受美罗华联合 CEOP方案治疗为治疗组 ;17例接受联合化疗为对照组 ;实验组患者接受 4～ 6周期美罗华 +CEOP方案治疗 ,每 1周期 2 1天 ,于每 1周期的第 1天给予美罗华 (375 m g/ m2 )静脉滴注 ,第 3天开始 CEOP方案化疗 ;对照组患者在接受 CEOP方案 (同上 )基础上加用博莱霉素 (10 m g/ m2 )、依托泊苷 (6 0 m g/ m2 )或卡氮芥 (80 mg/ m2 ) ,治疗周期为 4～ 6周期 ,每 1周期 2 1天。结果 :治疗组完全缓解率 (CR) 83.3% ,平均缓解时间 (16 .2±4 .6 )月 ;对照组完全缓解率 (CR) 2 3.5 % ,平均缓解时间 (4 .2 5± 2 .5 )月。表明接受美罗华联合 CEOP方案治疗组其完全缓解率及缓解时间明显高于对照组 (P<0 .0 5 )。结论 :美罗华联合 CEOP方案 ,可使复发性非霍奇金淋巴瘤患者再次获得较好疗效 。
Objective:To evaluate the safety and efficacy of the combination of rituximab and CEOP chemotherapy in patients with relapsed non Hodgkin's lymphoma(NHL).Methods:To choose 23 patients with relapsed B cell NHL as research objects,they are divided into two groups:treatment and control group.The treatment group (6 patients) received the combination of rituximab and CEOP chemotherapy;the control group (17 patients) received combination chemotherapy.The treatment group received 4～6 cycles of rituximab～CEOP combination therapy,there are twenty one days in each cycle,of each cycle,a dose of rituximab (375 mg/m 2)was infused on day 1;from day 3 CEOP chemotherapy was followed.The control group was administrated 4～6 cycles of CEOP chemotherapy and bleomycin 10 mg/m 2,etoposide 60 mg/m 2,carmustine 80 mg/m 2,each cycle consisted of twenty one days.Results:The complete response,the median duration of response were 83.3 %,(16.2±4.6)months in the treatment group,while in the control group they were 23.5 %,4.25±2.5,respectively.They were higher in the experiment group than those of the control group ( P <0.05)。Conclusion:Rituximab in combination with CEOP made patients with relapsed NHL achieve good efficacy,and no significant toxicity was found.
出处
《白血病．淋巴瘤》
CAS
2003年第4期215-217,共3页
Journal of Leukemia & Lymphoma
关键词
非霍奇金淋巴瘤
美罗华
化疗
Non Hodgkin's lymphoma
Rituximab
Chemotherapy
